Novartis, the global pharmaceutical and healthcare company based in Switzerland, announced today (4 December) a multi-year strategic collaboration with Amazon Web Services (AWS) as part of its continuous effort to transform its manufacturing, supply chain, and delivery operations of drugs.

Shahram Ebadollahi,
Novartis’ Head of Data Science and AI

A new platform to benefit patients

The new platform, backed by artificial intelligence (AI) and Internet of Things (IoT) solutions, aim to make new treatments and medications available to patients faster.

As part of this collaboration, “Insights Centers” that render on the spot reports of what goes on at Novartis’ global manufacturing operations and business across distribution centers will be built. These new units enable the planning teams “to better forecast and track production lines, detect potential bottlenecks, and perform predictive maintenance of machines, and making automated adjustments to improve accuracy”.

Novartis is also planning to use the AWS IoT services to visualize data and generate computer vision algorithms that look for possible risks such as out of stock inventory, delayed orders, and unplanned downtime, occur during manufacturing. Overall, the collaboration will be the foundation for customized, cloud-based solutions that will increase the agility, innovation and cost-efficiencies of Novartis’ multinational business processes and systems.

An age of transformation

In an interview with AIMed, Shahram Ebadollahi, Novartis’ Head of Data Science and AI said this strategic alliance is in line with the company’s digital transformation. Currently, Novartis is not only going after solution building but also adopting a data science and machine learning driven mindset at an enterprise level.

“As such, we only want to work with the best partner; one that has the best capabilities and tools. Collaborating with AWS allows us to leverage their infrastructure and expertise, which complement our technical operations and facilitate the co-development of Insights Centers”, Ebadollahi explains.

“At the same time, we are exposed to, and learn how, some of these technologies are established internally, and the potential opportunities that arise. All this is valuable as we use new technologies to reimagine the way we manufacture medicines and accelerate our digital transformation ”.

Author Bio

Hazel Tang A science writer with data background and an interest in the current affair, culture, and arts; a no-med from an (almost) all-med family. Follow on Twitter.